Markus Hecht, MD, PhD, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany, outlines the rationale of combining immunotherapy and radiotherapy in patients with head and neck cancer. Radiotherapy results in changes in the tumor microenvironment that may lead to an improved response to immune checkpoint blockade. Dr Hecht also touches on the importance of targeting novel checkpoint blockades in the future to optimize treatment approaches. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.